ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6385 participants.
Also called NCT05021835
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,385 participants
- Sponsor
- Registry
-
NCT05021835 -
jRCT2021210033
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05021835. Randomized; quadruple masking; primary purpose treatment. Start 2021-08-30 (actual); primary completion 2026-06-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
- Acronym
- ZEUS
- Condition
- Cardiovascular Risk
- Condition
- Chronic Kidney Disease
- Condition
- Inflammation
- Intervention (Drug)
- Ziltivekimab B
- Intervention (Drug)
- Ziltivekimab C
- Intervention (Drug)
- Placebo (Ziltivekimab B)
- Intervention (Drug)
- Placebo (Ziltivekimab C)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05021835- Content hash
0cea02727d86867e78bef0abc899f08aa06f3eda9fb0c36db95ac2ab51c77316